Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Cancer: Page 5
Illumina unveils new version of liquid biopsy assay
By
Matt Limb
Genomics company Illumina has announced a new generation of its distributed liquid biopsy assay for the genomic profiling of solid tumors.
November 8, 2023
Blood test for biomarker offers route to affordable cancer screening
By
Nick Paul Taylor
Researchers have developed a sensitive blood test for a highly specific biomarker of multiple common tumors, laying the groundwork for a product that could improve cancer screening.
November 6, 2023
Flatiron Health, Guardant Health to integrate tests, EMR platform
By
LabPulse.com staff writers
Flatiron Health and Guardant Health have signed an agreement to integrate Guardant’s genomic profiling test portfolio into Flatiron’s cloud-based OncoEMR electronic medical record (EMR) platform.
November 1, 2023
Targeting feeder cells reverses prostate cancer’s resistance to treatment in study
By
Matt Limb
Scientists have found a way to reverse prostate cancer’s resistance to drugs in research, which they say could have a broad impact across multiple cancer types.
October 24, 2023
Boehringer Ingelheim, Thermo Fisher to collaborate on CDx development for NSCLC
By
LabPulse.com staff writers
Boehringer Ingelheim and Thermo Fisher have formed a partnership to develop companion diagnostic (CDx) tests for identifying patients with non-small cell lung cancer (NSCLC) with specific genomic mutations who may benefit from targeted therapies.
October 19, 2023
Dxcover targets 2025 launch for blood test that uses light to detect cancer
By
Nick Paul Taylor
Dxcover is aiming to launch its brain cancer blood test to support the triage of symptomatic patients in Europe in 2025.
October 12, 2023
Aventa Genomics launches NGS test for solid tumors
By
LabPulse.com staff writers
Aventa Genomics has launched Aventa FusionPlus, a next-generation sequencing (NGS) test for the detection of gene fusions, translocations, and rearrangements across 361 genes from the formalin-fixed, paraffin-embedded tissue of solid tumors.
October 6, 2023
FDA authorizes Invitae hereditary cancer panel
By
Nick Paul Taylor
The U.S. Food and Drug Administration (FDA) has granted de novo authorization to an Invitae panel that tests for hundreds of genetic variants that indicate whether a person has a higher risk of developing certain cancers.
October 5, 2023
Genomic Health to pay $32.5M to settle False Claims Act allegations
By
LabPulse.com staff writers
Genomic Health, a subsidiary of Exact Sciences, has agreed to pay $32.5 million to settle allegations by the U.S. Department of Justice that it violated the False Claims Act by engaging in a scheme to improperly bill Medicare for laboratory tests.
October 4, 2023
Thermo Fisher receives FDA clearance for neuroendocrine tumor assay
By
LabPulse.com staff writers
Thermo Fisher has received clearance from the U.S. Food and Drug Administration (FDA) for its Brahms chromogranin A (CgA) II Kryptor test, a CgA immunoassay for assessing tumor progression in gastroenteropancreatic neuroendocrine tumor patients.
October 2, 2023
AI model reveals kidney tumor features, potential for treatment response prediction
By
LabPulse.com staff writers
Researchers at the Dana-Farber Cancer Institute have trained artificial intelligence (AI) models to assess the clinical features of kidney cancer tumor samples to predict how tumors may respond to immune therapy.
September 22, 2023
Consumer genetic testing may misrepresent breast cancer risk: Study
By
Matt Limb
Women are being told they are at high risk of breast cancer from consumer genetic test results which do not take family history into account, say researchers.
September 21, 2023
Previous Page
Page 5 of 96
Next Page
